LI-RADS Treatment Response Algorithm v2024 for Post-Treatment Assessment of Hepatocellular Carcinoma: A Systematic Review Across CEUS, CT/MRI, and Locoregional Therapies
Livers · 14.07.2026 · 6 (4) · 68
DOI: 10.3390/livers6040068 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Livers, online erschienen am 14.07.2026. Verfasst von Andrea Boccatonda und 4 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Accurate post-treatment imaging assessment of hepatocellular carcinoma (HCC) is essential for guiding retreatment, transplantation eligibility, and prognosis. The Liver Imaging Reporting and Data System Treatment Response Algorithm (LI-RADS TRA) was updated in 2024, introducing refinements across contrast-enhanced ultrasound (CEUS), CT/MRI, and radiation-based therapies, including the TR-Nonprogressing category. We aimed to systematically review current evidence on the diagnostic performance, reproducibility, and clinical implications of LI-RADS TRA v2024 for post-treatment assessment of HCC across imaging modalities and locoregional therapies.
Methods
A systematic search of PubMed, Embase, Scopus, Web of Science, and CENTRAL was conducted according to PRISMA 2020 guidelines. Original studies applying LI-RADS TRA v2024 (or comparisons with earlier versions or mRECIST) after locoregional therapies were included. Outcomes of interest comprised diagnostic accuracy metrics, inter-reader and inter-modality agreement, temporal behavior of TRA categories, and prognostic associations. Given substantial heterogeneity, results were synthesized narratively.
Results
Six studies met inclusion criteria. After thermal ablation, CEUS applying the non-radiation TRA v2024 showed very high specificity (approximately 88–100%) and excellent negative predictive value (about 94–98%), with substantial-to-almost-perfect inter-reader agreement (κ up to 0.92) and excellent inter-modality agreement with CT/MRI (ICC ≈ 0.90). After transarterial chemoembolization, CEUS performance was time-dependent, with higher sensitivity at early follow-up (~15 days) and higher specificity at later assessment (~30 days). On MRI, non-radiation TRA v2024 combined with ancillary features improved sensitivity and, in some analyses, accuracy compared with v2017 and v2024 without ancillary features, while remaining more specific than mRECIST. In radiation-based therapies, the radiation TRA v2024 captured delayed-response patterns through the TR-Nonprogressing category, which demonstrated meaningful temporal evolution and prognostic separation from TR-Viable. Surgical validation confirmed preserved diagnostic performance against histology.
Conclusions
Despite heterogeneous data, available evidence supports LI-RADS TRA v2024 as a clinically useful framework that improves clarity, reproducibility, and actionability of post-treatment HCC imaging. CEUS is particularly effective after ablation; timing is critical after TACE, ancillary features should be routinely applied on MRI, and TR-Nonprogressing appropriately reflects radiation biology while preserving prognostic value.
Zitieren
APA
Boccatonda, A., Brighenti, A., Bakken, S. M., Serra, C., & Piscaglia, F. (2026). LI-RADS Treatment Response Algorithm v2024 for Post-Treatment Assessment of Hepatocellular Carcinoma: A Systematic Review Across CEUS, CT/MRI, and Locoregional Therapies. Livers, 6(4), 68. https://doi.org/10.3390/livers6040068
Vancouver
Boccatonda A, Brighenti A, Bakken SM, Serra C, Piscaglia F. LI-RADS Treatment Response Algorithm v2024 for Post-Treatment Assessment of Hepatocellular Carcinoma: A Systematic Review Across CEUS, CT/MRI, and Locoregional Therapies. Livers. 2026;6(4):68. doi:10.3390/livers6040068
BibTeX
@article{Boccatonda2026,
author = {Boccatonda, Andrea and Brighenti, Alice and Bakken, Sofia Maria and Serra, Carla and Piscaglia, Fabio},
title = {LI-RADS Treatment Response Algorithm v2024 for Post-Treatment Assessment of Hepatocellular Carcinoma: A Systematic Review Across CEUS, CT/MRI, and Locoregional Therapies},
journal = {Livers},
year = {2026},
volume = {6},
number = {4},
pages = {68},
doi = {10.3390/livers6040068}
}
EUVIMED